Clear All
793 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan 1, 2004 Dec 31, 2004 No Longer Used
J8999 Chemotherapy - non specific Prescription drug, oral, chemotherapeutic NOS NA Chemotherapy Yes In Use
NA Cysteamine Bitartrate Cystagon 50mg, 150mg Chemotherapy Cystine-Depleting Agent Yes 1994 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
J9098 Cytarabine Cytarabine Liposome 10 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1999 Jan 1, 2004 Jan 12, 2026 In Use
J9120 Dactinomycin Cosmegen 0.5 mg Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1964 Jan 1, 1984 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
J1453 Fosaprepitant Emend 150 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2008 Jan 1, 2009 In Use
J9179 Eribulin mesylate Halaven 0.1 mg Chemotherapy Antimitotic Agent Furopyrans No 2010 Jan 1, 2012 In Use
J0202 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2016 In Use
NA Cyclosporine Sandimmune 25mg, 50mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1983 In Use
C9414 Etoposide Toposar 50 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins Yes 1986 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 Jul 1, 2020 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
C9415 Doxorubicin Adriamycin 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1989 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
S0190 Mifepristone Korlym, Mifeprex 200 mg Hormonal Therapy Antiprogestin Cortisol Receptor Blocker Yes 2000 Jan 1, 2001 In Use
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
J9024 Atezolizumab, hyaluronidase-tqjs Tecentriq Hybreza 5mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2024 Mar 26, 2025 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA cobimetinib Cotellic 20 mg Chemotherapy MAPK/MEK Inhibitor BRAF Yes 2015 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.